Equine herpesviruses 1 and 4: creeping to a solution.

The research discusses the combined effort in understanding the equine herpesviruses 1 and 4, primarily focusing on its epidemiology, pathologies, and immunoprophylaxis. The potentially devastating diseases associated with these viruses have led to more comprehensive study methods integrating specialized skills from various professionals, improving diagnosis, tracking, and understanding the disease and how it infects.

Understanding Equine Herpesviruses

• The article starts by discussing the history of equine herpesviruses (EHV-1 and EHV-4) research, initiated when EHV-1 was first associated with horse abortions in 1932. The continuing research has been a collaborative effort from the equine industry, pharmaceutical companies, and various funding bodies highlighting the importance of long-term research and funding.
• EHV-1 and EHV-4 inflict different clinical syndromes, from silent infections to severe respiratory disease, including consequential effects of abortion or paralysis in horses. Interestingly, the varied clinical outcomes are associated with the type of cells the viruses chose to infect, specifically, the study found that viral preference for infection of vascular endothelial cells being a feature of high virulence EHV-1.

Research Findings

• Various experimental studies primarily focus on high virulence EHV-1, revealing some of the mechanisms through which it causes disease. However, understanding of how low-endotheliotropism EHV-1 causes abortion is still emerging. Also, there is progress in creating in vitro models to help further this understanding, promoting strategies that reduce the use of animals in veterinary research.
• Development and application of PCR-based assays for studying EHV-1 and its epidemiology have provided new insights. These assays enabled the researcher to categorize EHV-1 into different phylogenetic groups and discover certain genetic differences in isolates associated with paralytic disease. This could revolutionize the diagnosis of EHV-1, prevalence assessment of latently infected horses, and the monitoring of exposed horses after disease cessation.
• The potential for PCR-based technologies in research is shown by a recent discovery that EHV-4 can be found in foals as young as 11 days old, suggesting the infection cycle may occur very early in the lives of horses.

Effective Control Strategies

• Experiments performed earlier clarified the possibility of EHV-1 causing abortion due to vasculitis and thrombosis in the pregnant uterus that resulted in placental separation without any detectable virus transfer to the fetus. More recent studies have confirmed this occurrence of EHV-1 abortion, sparking renewed interest in the role of the placenta in this disease.
• Immunoprophylaxis against EHV-1 and EHV-4 has been challenging due to complications in demonstrating immune responses. Detailed studies to assess EHV-1 abortion vaccines found that levels of circulating complement-fixing antibodies do not fully correlate with protection. However, more recent work identified the crucial role of cytotoxic T-lymphocytes in susceptibility to infection.
• The continuous study on EHV-1 and EHV-4 has opened new paths for novel vaccine design, promising key breakthroughs in formulating effective control strategies against these diseases in horses.